Corvidia Therapeutics to Present on Novel Anti-Inflammatory Therapy for Cardio-Renal Disease at J.P. Morgan Healthcare Conference


WALTHAM, Mass., Jan. 4, 2019 /PRNewswire/ -- Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, will present its work on an investigational cardio-renal therapy being developed to address residual inflammatory cardiovascular risk in patients living with Chronic Kidney Disease (CKD) at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco next week. 

Chief Executive Officer Marc de Garidel will share details on Corvidia's multi-scale approach utilizing genomic, phenomic and interventional evidence in the development of precision medicines for cardio-renal patients. Corvidia's lead asset, ziltivekimab, is an anti-inflammatory monoclonal antibody targeting a patient population genetically-susceptible to the effects of a specific type of inflammation.

Inflammation has been established as a causal factor in the residual risk of cardiovascular patients, particularly within the context of chronic kidney disease, with a susceptible population of over a million patients worldwide. Corvidia is developing evidence for Interkleukin-6 as a factor in this inflammatory cardiovascular risk in patients with CKD who carry both genetic and clinical risk characteristics. Mr. de Garidel will offer insight into how Corvidia Therapeutics is utilizing a combination of genomics and patient risk factor analysis to develop its lead asset for patients living with CKD.

Presentation Details 

DATE: Thursday, January 10, 2019

TIME: 10:30 am PST

LOCATION: Elizabethan D, Westin St. Francis Hotel, San Francisco

About Corvidia Therapeutics Inc. 

Corvidia Therapeutics Inc. is a clinical stage biotechnology company based in Waltham, Massachusetts pioneering the next generation of cardio-renal therapies. Corvidia's pipeline programs utilize functional genomics to identify patients with sensitivity to specific biologic pathways, allowing for efficient development and path-to-market for drugs targeting those pathways. Among our portfolio of innovative therapeutic candidates, we presently have an experimental therapy in Phase 2 development for a genetically-defined patient population with chronic kidney disease. Corvidia's other preclinical programs are in various stages of pre-clinical development and are focused on cardiovascular diseases. For more information, please visit

Press Inquiries:

McDougall Communications on behalf of Corvidia Therapeutics Inc.  
Contact: Elizabeth Harness,, Tel: +1 (585) 435 -7379